8-K: Sangamo Therapeutics Files for Chapter 11, Faces Nasdaq Delisting

Sangamo Therapeutics has filed for Chapter 11 bankruptcy and its stock now trades on the OTCID Basic Market, while a Nasdaq delisting appeal is pending.

Summary

• Sangamo Therapeutics, Inc. (the Company) received a notification from Nasdaq on April 28, 2026, regarding its determination to delist the Company's common stock due to a failure to meet the minimum bid price requirement.
• The Company's common stock was suspended from trading on Nasdaq and began trading on the OTCQB Venture Market on May 5, 2026.
• Following the filing of a voluntary petition for bankruptcy under Chapter 11 on June 24, 2026, the Company's common stock began trading on the OTCID Basic Market under the symbol SGMOQ.
• The Company's appeal of the Nasdaq delisting determination is still pending.
• On June 25, 2026, the Audit Committee of the Board of Directors terminated the engagement of Ernst & Young LLP (EY) as the Company's independent registered public accounting firm.
• EY's reports for fiscal years ended December 31, 2024, and December 31, 2025, included an explanatory paragraph regarding the Company's ability to continue as a going concern.
• There were no disagreements with EY on accounting principles or practices, financial statement disclosure, or auditing scope or procedure during the relevant periods.
• EY has confirmed agreement with the statements made in the 8-K filing regarding the change in accountants.

Sentiment

Score: 1

Explanation: StockSavvy.ai views this filing as extremely negative, indicating severe financial distress, bankruptcy, and delisting from a major stock exchange.

Negatives

• The Company received a determination from Nasdaq to delist its common stock due to failure to comply with the minimum bid price requirement.
• The Company's common stock was suspended from trading on Nasdaq.
• The Company has filed for voluntary bankruptcy under Chapter 11.
• The Company's common stock is now trading on the OTCID Basic Market.
• EY's reports on the Company's financial statements contained an explanatory paragraph regarding the Company's ability to continue as a going concern.

Risks

• The ongoing failure to comply with Nasdaq's minimum bid price requirement could lead to delisting.
• The Chapter 11 bankruptcy filing introduces significant uncertainty regarding the Company's future operations and financial stability.
• The outcome of the Nasdaq appeal remains pending, creating uncertainty about the future listing of the Company's stock.
• The inability to secure a new independent registered public accounting firm could impact future financial reporting and compliance.

Future Outlook

The future outlook for Sangamo Therapeutics is highly uncertain due to the Chapter 11 bankruptcy filing and the pending Nasdaq delisting appeal. The company's ability to continue as a going concern was previously noted by its auditors.

Management Comments

• The Company's common stock remains listed on the Nasdaq Capital Market, as the delisting determination issued by Nasdaq on April 28, 2026 has been stayed pending the outcome of the Company's appeal before the Nasdaq Hearings Panel.

Industry Context

StockSavvy.ai notes that this filing highlights significant distress for Sangamo Therapeutics, a company operating in the highly competitive and capital-intensive biotechnology sector. The delisting and bankruptcy filing suggest severe financial challenges, potentially impacting its ability to fund ongoing research and development or attract new investment, a common risk for companies in this space facing clinical or financial setbacks.

Corporate Governance

Legal Proceedings

• The Company has filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code (Case No. 26-10989).

Stakeholder Impact

• Shareholders: Significant loss of value due to bankruptcy and delisting; potential for complete loss of investment.
• Creditors: The Chapter 11 filing initiates a process to restructure debt, impacting the recovery of amounts owed.
• Employees: Job security and compensation are at high risk due to bankruptcy proceedings.
• Suppliers: Payment for goods and services may be impacted by the bankruptcy filing.

Next Steps

• The outcome of the Nasdaq appeal remains pending.
• A new independent registered public accounting firm has not yet been engaged.

Key Dates

Recommendation

The filing indicates severe financial distress, including a Chapter 11 bankruptcy filing and a Nasdaq delisting determination. These factors present substantial risks to the company's viability and shareholder value, warranting a sell recommendation.

Keywords

Sangamo Therapeutics, 8-K, Chapter 11 Bankruptcy, Nasdaq Delisting, OTC Market, Ernst & Young, Going Concern, Financial Reporting, Securities Exchange Act